Video

Dr. Yang on the Current Treatment Landscape in MCL

Author(s):

Jay Yang, MD, discusses the current treatment landscape of mantle cell lymphoma.

Jay Yang, MD, oncologist, Malignant Hematology, the Karmanos Cancer Institute, discusses the current treatment landscape of mantle cell lymphoma (MCL).

Compared with other types of lymphoma, MCL is unique in the sense that it does not have a true standard of care, Yang says. This is partially due to the heterogeneity of MCL, since the presentation of the disease, its prognosis, and therapies can all vary, leading to a range of long-term outcomes, Yang explains.

Although some patients with MCL have such indolent disease that they can be observed initially without any therapy, most patients with MCL will need treatment, Yang concludes.

Related Videos
James J. Harding, MD, associate attending physician, Memorial Sloan Kettering Cancer Center
J. Bradley Elder, MD
Rimas V. Lukas, MD
Adam E. Singer, MD, PhD, Health Sciences Clinical Instructor, medicine, division lead, kidney cancer, Division of Hematology/Oncology, UCLA Health
Diane Reidy-Lagunes, MD, vice chair, Oncology Operations, Regional Care Network, Memorial Sloan Kettering Cancer Center
Shubham Pant, MD, MBBS
Kevin Kalinsky, MD, MS, professor, Department of Hematology and Medical Oncology, director, Division of Medical Oncology, Department of Hematology and Medical Oncology, Emory University School of Medicine; Louisa and Rand Glenn Family Chair in Breast Cancer Research, director, Glenn Family Breast Center, director, Breast Medical Oncology, Winship Cancer Institute of Emory University
Brett L. Ecker, MD
Benjamin Garmezy, MD, assistant director, Genitourinary Research, Sarah Cannon Research Institute
Yelena Y. Janjigian, MD, chief, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center